日本の糖尿病市場レポート：2024年～2032年

日本の糖尿病市場の市場規模は2023年に54億米ドルに達しました。今後、IMARC Groupは、同市場が2032年までに73億米ドルに達し、2024年から2032年の間に3.3%の成長率（CAGR）を示すと予測しています。

糖尿病とは、インスリンホルモンを分泌し、それに反応する人体の能力が低下する慢性疾患を指します。その結果、炭水化物の代謝に異常が生じ、血液中のグルコース濃度が上昇します。日本では、人口の大部分が60歳以上であり、2型糖尿病が多発する年齢です。さらに、日本人の食生活は白米や麺類など精製された炭水化物の割合が高いため、糖尿病を発症したり悪化させたりするリスクが高いです。

日本の糖尿病市場 促進要因：

促進要因：西洋料理の影響の拡大、労働時間の増加、国内農業生産の減少に伴い、消費者はハンバーガー、タコス、ホットドッグ、ピザなどの加工食品やファーストフードに頼るようになっています。これらの食品には炭水化物、ナトリウム、保存料が多く含まれているため、消費量の増加により糖尿病の患者が増加しています。糖尿病患者を増加させているその他の要因としては、肥満人口の増加や座りがちなライフスタイルなどが挙げられます。しかし、糖尿病の有病率を最小限に抑えるため、日本政府はいくつかの取り組みを行っています。例えば、国民皆保険制度を通じて、日本に1年以上居住する市民と非市民の両方に健康保険を提供しています。

本レポートで扱う主な質問

• 日本の糖尿病市場はこれまでどのように推移し、今後どのように推移していくのか？
• COVID-19が日本の糖尿病市場に与えた影響は？
• 日本の糖尿病市場で人気のあるセグメントは？
• 日本糖尿病市場のバリューチェーンにおける様々な段階とは？
• 日本の糖尿病市場における主要な推進要因と課題は何か？
• 日本の糖尿病市場の構造と主要プレイヤーは？
• 日本の糖尿病市場における競争の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

• 調査の目的
• ステークホルダー
• データソース
  • 一次情報
  • 二次情報
• 市場推定
  • ボトムアップアプローチ
  • トップダウンアプローチ
• 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

• 概要
• 主要業界動向

第5章 糖尿病疾患の概要

• 糖尿病とは何ですか?
• 糖尿病の診断と治療
  • 診断
  • 治療
• 糖尿病の合併症

第6章 日本糖尿病疫学

• 糖尿病人口と有病率
• 人口と有病率：糖尿病の種類別（1型と2型）
• 人口と罹患率：地域別
• 人口と罹患率：男女別
• 人口と罹患率：年齢別

第7章 日本の糖尿病市場

• 市場概要
• 市場実績
• COVID-19の影響
• 市場予測
• SWOT分析
  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威
• バリューチェーン分析
• ポーターのファイブフォース分析
  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威
• 市場内訳：セグメント別
  • 日本の経口糖尿病薬市場
    • 過去の市場動向
    • 市場内訳：クラス別
    • 主要企業の市場シェア
    • 市場予測
  • 日本のインスリン市場
    • 過去の市場動向
    • 市場内訳：クラス別
    • 主要企業の市場シェア
    • 市場予測

第8章 競合情勢

• 市場構造
• 主要企業のプロファイル

List of Figures

• Figure 1: The Impact of Diabetes in the Human Body
• Figure 2: Diabetes Complications
• Figure 3: Global: Breakup of Diabetes Patients by Region, (in %) 2023 & 2032
• Figure 4: Body Mass Index and Relative risk of Type-2 Diabetes
• Figure 5: Japan: Total Number of Diabetes Patients (in 000), 2018-2023
• Figure 6: Japan: Total Number of Diabetes Patients Forecast (in 000), 2024-2032
• Figure 7: Japan (Type1 & Type2): Total Number of Diabetes Patients (in 000), 2018-2023
• Figure 8: Japan (Type1 & Type2): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
• Figure 9: Japan (Urban & Rural): Total Number of Diabetes Patients (in 000), 2018-2023
• Figure 10: Japan (Urban & Rural): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
• Figure 11: Japan (Male & Female): Total Number of Diabetes Patients (in 000), 2018-2023
• Figure 12: Japan (Male & Female): Total Number of Diabetes Patients Forecast (in 000), 2024-2032
• Figure 13: Japan: Total Number of Diabetes Patients by Age Group (20-39), (40-59) & (60-79) (in 000), 2018-2023
• Figure 14: Japan: Total Number of Diabetes Patients Forecast by Age Group (20-39), (40-59) & (60-79) (in 000), 2024-2032
• Figure 15: Japan: Diabetes Drug Industry Overview
• Figure 16: Japan: Diabetes Drug Market: Sales Value (in Billion US$), 2018-2023
• Figure 17: Japan: Diabetes Drug Market Forecast: Sales Value (in Billion US$), 2024-2032
• Figure 18: Japan: Diabetes Drug Market: SWOT Analysis
• Figure 19: Japan: Diabetes Drug Market: Value Chain Analysis
• Figure 20: Japan: Diabetes Drug Market: Porters Five Forces Analysis
• Figure 21: Japan: Diabetes Drug Market: Breakup of Insulin and Oral Antidiabetics (in %), 2018-2023
• Figure 22: Japan: Diabetes Drug Market Forecast: Breakup of Insulin and Oral Antidiabetics (in %), 2024-2032
• Figure 23: Japan: Oral Antidiabetics Market: Sales Value (in Million US$), 2018-2023
• Figure 24: Japan: Oral Antidiabetics Market: Sales Share of Key Classes (in %), 2018 & 2023
• Figure 25: Japan: Oral Anti-diabetics Market: Sales Share of Key Players (in %)
• Figure 26: Japan: Oral Antidiabetics Market Forecast: Sales Value (in Million US$), 2024-2032
• Figure 27: Japan: Insulin Market: Sales Value (in Million US$), 2018-2023
• Figure 28: Japan: Breakup of Insulin Market by Class (in %), 2023
• Figure 29: Japan: Insulin Market: Sales Share of Key Players (in %)
• Figure 30: Japan: Insulin Market Forecast: Sales Value (in Million US$), 2024-2032

List of Tables

• Table 1: Diagnosis of Diabetes
• Table 2: Global: Diabetes Population Breakup by Country (in 000's), 2023 and 2032
• Table 3: Japan: Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
• Table 4: Japan (Type1 & Type2): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
• Table 5: Japan (Urban & Rural): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
• Table 6: Japan (Male & Female): Total Prevalence & Number of Diabetes Patients, 2018, 2023 & 2032
• Table 7: Japan: Total Prevalence & Number of Diabetes Patients by Age Group (20-39, 40-59, 60-79 - In Millions), 2018, 2023 & 2032
• Table 8: Japan: Diabetes Drug Market: Competitive Structure

The Japan diabetes market size reached US$ 5.4 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 7.3 Billion by 2032, exhibiting a growth rate (CAGR) of 3.3% during 2024-2032.

Diabetes refers to a chronic disease in which the ability of a human body to produce and respond to insulin hormone becomes impaired. This results in abnormal metabolism of carbohydrates and elevated levels of glucose in the blood. In Japan, a large section of the population is over 60 years, an age when type-2 diabetes becomes more prevalent. Moreover, as the Japanese diet consists of a significant portion of refined carbohydrates, like white rice and noodles, it puts the population at a higher risk of developing and aggravating diabetes.

Japan Diabetes Market Drivers:

With the growing influence of western cuisines, increasing working hours and declining domestic agricultural production, consumers are now relying on processed food products and fast-food like burger, taco, hotdog and pizza. As these food products are high in carbohydrates, sodium and preservatives, their rising consumption has increased the cases of diabetes in the country. The other factors that are contributing to the increasing cases of diabetes include growing obese population and sedentary lifestyles. However, to minimize the prevalence of diabetes in the country, the Government of Japan is undertaking several initiatives. For instance, it is offering health insurance to both the citizens and non-citizens residing for more than a year in Japan through their universal health care system.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the Japan diabetes market report, along with forecasts for the period 2024-2032. Our report has categorized the market based on segment.

Breakup by Segment:

Oral Antidiabetics

Insulin

Currently, insulin represents the dominant segment, accounting for the majority of the total market share. Insulin in Japan is usually taken through pens, pumps, syringes and jet injectors as they offer convenience to the patients. Increasing diagnostic rates and awareness among patients are enabling them to incorporate insulin therapy for treating diabetes.

Competitive Landscape:

The competitive landscape of the market has been analyzed in the report with detailed profiles of key players operative in the industry.

Key Questions Answered in This Report:

• How has the Japan diabetes market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the Japan diabetes market?
• Which are the popular segments in the Japan diabetes market?
• What are the various stages in the value chain of the Japan diabetes market?
• What are the key driving factors and challenges in the Japan diabetes market?
• What is the structure of the Japan diabetes market and who are the key players?
• What is the degree of competition in the Japan diabetes market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Diabetes Disease Overview

• 5.1 What is Diabetes?
• 5.2 Diabetes Diagnosis and Treatment
  • 5.2.1 Diagnosis
  • 5.2.2 Treatment
• 5.3 Diabetes Complications

6 Japan Diabetes Epidemiology

• 6.1 Diabetes Population and Prevalence Rates
• 6.2 Population and Prevalence Rates by Diabetes Type (Type-1 and Type-2)
• 6.3 Population and Prevalence Rates by Region
• 6.4 Population and Prevalence Rates by Gender
• 6.5 Population and Prevalence Rates by Age Group

7 Japan Diabetes Market

• 7.1 Market Overview
• 7.2 Market Performance
• 7.3 Impact of COVID-19
• 7.4 Market Forecast
• 7.5 SWOT Analysis
  • 7.5.1 Overview
  • 7.5.2 Strengths
  • 7.5.3 Weaknesses
  • 7.5.4 Opportunities
  • 7.5.5 Threats
• 7.6 Value Chain Analysis
• 7.7 Porter's Five Forces Analysis
  • 7.7.1 Overview
  • 7.7.2 Bargaining Power of Buyers
  • 7.7.3 Bargaining Power of Suppliers
  • 7.7.4 Degree of Competition
  • 7.7.5 Threat of New Entrants
  • 7.7.6 Threat of Substitutes
• 7.8 Market Breakup by Segment
  • 7.8.1 Japan Oral Antidiabetics Market
    • 7.8.1.1 Historical Market Trends
    • 7.8.1.2 Market Breakup by Class
    • 7.8.1.3 Market Shares of Key Players
    • 7.8.1.4 Market Forecast
  • 7.8.2 Japan Insulin Market
    • 7.8.2.1 Historical Market Trends
    • 7.8.2.2 Market Breakup by Class
    • 7.8.2.3 Market Shares of Key Players
    • 7.8.2.4 Market Forecast

8 Competitive Landscape

• 8.1 Market Structure
• 8.2 Profiles of Key Players